…At any rate, the NEJM article describes four bills as having been introduced in the U.S. Congress in 2007 to expedite approval of follow-on protein products. None reached the floor. The article cheerfully concludes “despite failures of the bills… [they] collectively represent important first steps that should help stimulate further discourse… and signal an end to the de facto permanent patent that a recombinant protein therapeutic currently enjoys.” In the meantime, its a hard knock life for persons with ultra-rare disorders. (photo credit: dishevld 2007)
BibTeX
@Manual{stream2008-167,
title = {Little Orphan Ending},
journal = {STREAM research},
author = {Jonathan Kimmelman},
address = {Montreal, Canada},
date = 2008,
month = mar,
day = 21,
url = {http://www.translationalethics.com/2008/03/21/little-orphan-ending/}
}
MLA
Jonathan Kimmelman. "Little Orphan Ending" Web blog post. STREAM research. 21 Mar 2008. Web. 10 Jan 2025. <http://www.translationalethics.com/2008/03/21/little-orphan-ending/>
APA
Jonathan Kimmelman. (2008, Mar 21). Little Orphan Ending [Web log post]. Retrieved from http://www.translationalethics.com/2008/03/21/little-orphan-ending/
Leave a Reply